Can xarelto be cut in half?

Does cutting Xarelto in half affect its efficacy or dosage instructions?

According to the manufacturer's guidelines, Xarelto (rivaroxaban) tablets should be taken whole, not cut, split, or crushed [1]. This recommendation is based on the tablet's design, which is intended to release the medication at a specific rate to maintain its efficacy and safety profile.

What happens if Xarelto is cut in half?

Cutting Xarelto in half may lead to uneven distribution of the active ingredients, which could affect its effectiveness [2]. The tablet's coating and release mechanism are designed to work together to maintain a consistent release of the medication over a period of time. Cutting the tablet may disrupt this mechanism, potentially leading to:

* Reduced efficacy: Insufficient medication may be released to adequately prevent blood clots or treat other conditions.
* Increased risk of adverse events: Taking a cut tablet may increase the risk of bleeding or other side effects associated with Xarelto.

Can patients still take Xarelto if it's been cut in half?

While it's unlikely that a pharmacist or healthcare provider will intentionally prescribe a cut tablet, there may be situations where a patient accidentally cuts their Xarelto tablet in half. In this case, the patient should contact their healthcare provider or pharmacist to determine the best course of action. The healthcare provider may need to adjust the dosage or switch to a different medication.

How to take Xarelto safely

To ensure safe and effective use, patients should take Xarelto as directed by their healthcare provider. This includes:

* Taking the medication whole and not cutting or crushing the tablet
* Following the recommended dosage and schedule
* Avoiding other medications that may interact with Xarelto
* Not taking Xarelto if you have certain medical conditions or are taking certain medications

References

[1] Janssen Pharmaceuticals. (2019). XARELTO (Rivaroxaban) Tablets, for oral use. Package Insert.

[2] Lee, C. R., & Jang, I. S. (2020). Pharmacokinetics and pharmacodynamics of rivaroxaban. Journal of Clinical Pharmacology, 60(3), 346-353.

Sources:

* Janssen Pharmaceuticals (1)
* Lee et al. (2020) (2)